LAS VEGAS, NV--(Marketwire - 01/12/10) - QUADRA PROJECTS INC. ("Quadra" or the "Company") (OTC.BB:QPRJ - News) announces that the QES2000 Utility Unit has been completed and that in house testing is currently underway. Independent engineering testing is scheduled after completion of the in house testing. Immediately after certification of the QES Conversion Unit, it will be available for demonstration for the Company's prospective buyers and Government Authorities in the City of Guangzhou, located in Guangdong Province in the Peoples Republic of China.
Quadra's authorized distributor, Fanta International has advised that Municipal Solid Waste (MSW) is a major problem in the Guangzhou area with several thousand tons being generated each day. This could lead to sales of up to 100 QES2000 conversion units over the next 2 years generating sales in excess of 150 Million Dollars.
After testing in Guangzhou, the QES Utility Unit is to be relocated to Beijing where it will be used to demonstrate the technology for Government Environmental Authorities, Senior Regulatory Central Government Officials and qualified prospective joint venture partners. The Company's joint venture partner, Richbay Holdings Limited, will co-host the demonstration and has advised that the purpose of the testing is confirm viability of the technology, with the object of securing endorsement of the Central Government.
This endorsement could lead to significant sales in the Beijing area, where disposing of Municipal waste is a major problem.
Management of the Company is of the opinion that the patented QES2000 System is the most advanced pyrolysis and gasification system in the world, specifically designed to convert all organic waste such as palm husks (including used tires, plastic waste and municipal waste etc,) to valuable by-products such as N220 carbon black, biochar fertilizer, and/or fuel oil or fuel gas for the production of electrical power, without any measurable environmental pollution or ash to be land filled. The QES2000 System is designed to meet the Global challenges of the 21st Century wherein natural resources are being exhausted, the petroleum industry is unstable and uncertain in terms of cost and supply and the world is seeing a degradation of the Global environment.
Because of the affordability of the QES2000 System, and the creation of significant revenue streams from the by-products, the return on investment is much greater than other competitive systems.
QUADRA PROJECTS INC.
QUADRA PROJECTS INC. intends on becoming a leading green energy company focusing on environmentally friendly opportunities focusing on its leading waste to energy technology and other green industry opportunities existing world-wide.
Forward Looking Statements:
THIS RELEASE CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS CONCERNING QUADRA'S OPERATIONS, ECONOMIC PERFORMANCE AND FINANCIAL CONDITION. THESE STATEMENTS ARE BASED UPON A NUMBER OF ASSUMPTIONS AND ESTIMATES, WHICH ARE INHERENTLY SUBJECT TO UNCERTAINTIES AND CONTINGENCIES, MANY OF WHICH ARE BEYOND THE CONTROL OF THE COMPANY, AND REFLECT FUTURE BUSINESS DECISIONS, WHICH ARE SUBJECT TO CHANGE. SOME OF THESE ASSUMPTIONS MAY NOT MATERIALIZE, AND UNANTICIPATED EVENTS WILL OCCUR WHICH CAN AFFECT THE COMPANY'S RESULTS.
Tuesday, January 12, 2010
Sunday, January 10, 2010
Proton Laboratories, Inc. Announces the Acquisition of Regenobody S.A.
SOSUA BAY, Dominican Republic, Jan. 8, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI - News), a Washington corporation, today announced the acquisition of Regenobody S.A., a Dominican Republic company involved in some of the latest technologies associated with stem cell regeneration using the patient's own stem cells. Pursuant to the Agreement, the Company (PLBI) will issue 300,000,000 of its common shares to the Regenobody shareholders, which will result in the shareholders of Regenobody acquiring shareholder control of Proton Laboratories, Inc.
Armando Casciati, newly elected President of Proton Laboratories, Inc. stated that the new company will aggressively work toward completing the development of its laboratory and acquisition of the balance of the needed equipment from its Korean licensor and patent holder, RNLBIO. It is anticipated that a name change and symbol change will occur in the next 90 days. The prior Proton directors have resigned concurrent with the acquisition. More information may be seen at the Company's website www.regenobody.com.
The statements made in this release contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial conditions and other aspects of the company to which this release pertains. The actual results of specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although the statements are based upon the best judgments of management of the company as of the date of this release, significant deviation in magnitude, timing and other factors may result from business risks and uncertainties including without limitation, the company's dependence on third parties, market conditions, technical factors, the availability of outside capital and receipt of revenues, and other factors, many of which are beyond the control of the Company.
Armando Casciati, newly elected President of Proton Laboratories, Inc. stated that the new company will aggressively work toward completing the development of its laboratory and acquisition of the balance of the needed equipment from its Korean licensor and patent holder, RNLBIO. It is anticipated that a name change and symbol change will occur in the next 90 days. The prior Proton directors have resigned concurrent with the acquisition. More information may be seen at the Company's website www.regenobody.com.
The statements made in this release contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial conditions and other aspects of the company to which this release pertains. The actual results of specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although the statements are based upon the best judgments of management of the company as of the date of this release, significant deviation in magnitude, timing and other factors may result from business risks and uncertainties including without limitation, the company's dependence on third parties, market conditions, technical factors, the availability of outside capital and receipt of revenues, and other factors, many of which are beyond the control of the Company.
SK3 Group Announces Signing of Merger Agreement with Healthcare of Today, and Correction of Prior Acquisition Announcement
MIAMI, FLORIDA--(Marketwire - 01/08/10) - SK3 Group, Inc. (PINK SHEETS:SKTO - News) today announces that it has entered into a definitive Agreement and Plan of Merger with Healthcare of Today, Inc., completing the terms of the previously announced letter of intent. Closing of the merger is subject to the completion of audits of SK3 and Healthcare of Today, Inc., the effectiveness of an S-4 registration statement to be filed with the SEC, and acceptance of a listing application with NASDAQ for the common shares of the surviving entity in the merger. Under the terms of the merger, Healthcare of Today, Inc. and SK3 Group will both merge into a newly-formed Nevada corporation, Healthcare of Today, Inc., which has been formed for that purpose and which will be the surviving entity.
In addition, SK3 Group previously announced that Healthcare of Today, Inc. has acquired MacuCLEAR, Inc., a pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye. That announcement was incorrect. Healthcare of Today has, in fact, entered into a letter of intent for such an acquisition, but has not yet completed a definitive acquisition agreement or closed on the acquisition.
Healthcare of Today (http://www.healthcareoftoday.com), based in Burbank, California, is a vertically-integrated healthcare holding company. Founded in 2008, it has since acquired a number of companies, many specializing in the senior care industry. Its subsidiaries are engaged in a wide range of businesses including: nurse staffing, residential care facilities for the elderly, home healthcare services, home healthcare equipment sales, healthcare information technology, medical equipment, healthcare consulting, insurance, data security, advanced human tissue engineering, and more.
About SK3 Group, Inc.
SK3 Group also markets preferred medical services through its facilitation partners to its PEO client base. Corporate information can be found at http://www.sk3groupinc.com.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
In addition, SK3 Group previously announced that Healthcare of Today, Inc. has acquired MacuCLEAR, Inc., a pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye. That announcement was incorrect. Healthcare of Today has, in fact, entered into a letter of intent for such an acquisition, but has not yet completed a definitive acquisition agreement or closed on the acquisition.
Healthcare of Today (http://www.healthcareoftoday.com), based in Burbank, California, is a vertically-integrated healthcare holding company. Founded in 2008, it has since acquired a number of companies, many specializing in the senior care industry. Its subsidiaries are engaged in a wide range of businesses including: nurse staffing, residential care facilities for the elderly, home healthcare services, home healthcare equipment sales, healthcare information technology, medical equipment, healthcare consulting, insurance, data security, advanced human tissue engineering, and more.
About SK3 Group, Inc.
SK3 Group also markets preferred medical services through its facilitation partners to its PEO client base. Corporate information can be found at http://www.sk3groupinc.com.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Thursday, January 7, 2010
Sync2 Networks Develops Virtual Online Gaming Application with New JV Partner
LAS VEGAS, NEVADA--(Marketwire - 01/07/10) - Sync2 Networks Corp. (OTC.BB:SYNW - News) is implementing its restructuring program, with new JV Partnership.
Sync2 Networks, Develops Virtual Online Gaming Application, that will provide an integrated process for developing and distributing our applications through the AMPSC international agent network in over 20 countries. One of the company's key restructuring programs is being be implemented through the new Acquisition of the AMPSC Group lead by Sync2 networks, new president Mr. Ron Houle.
The JV partners in India will complement our North American team to provide a global application for our JV partners at VRX Simulators (www.vrx.ca) with such clients as Microsoft, Intel, AMD, Samsung, Indy and Nascar racing, just to name a few. This new virtual online gaming application will complement the Virtual Racer X Simulator platform.
This direction represents a corporate focus on the global gaming market and compliments the VRX Simulator partnership and development for a truly global application.
Mr. Houle has been working with VRX under a JV partnership with our Indian partners to develop an application to complement the VRX platform, where by the fiscal Racer X Racing simulator platform is used. Sync2 Networks with our India team will create a virtual online application where gaming and advertising come together and is fed directly into the online game as people around the world are playing in real time.
According to a recent report by market research firm iResearch currently, sales and subscriptions to Web-based games generate $353 million. Online-game advertisements generate between $450 million and $550 million, the research company said.
One segment that's giving the online-game industry a boost is "massively multiplayer online games". According to the Yankee study, in the United States alone, there will be 10 million people subscribing to these games by 2010, generating over $1.2 billion in revenue.
Last year, China's online gaming industry turned over 27.5 billion yuan (about 4.03 billion U.S. dollars) in 2009, according to Ma Huateng, president and CEO of China's leading Internet service provider Tencent Holdings Limited.
The global in-game advertising market, which generated $77.7 million globally in 2006, continues to develop at an exponential rate and will, by 2011, grow to $971.3 million in worldwide in-game advertising expenditures (fixed product placement/static ads and dynamic ads), according to a recent Yankee Group report.
About Sync2 Networks Corp.
Sync2 Networks is an online business development firm, which develops online Gaming and advertising applications. Sync2 through the AMPSC Group, also has a worldwide network of international marketing and business development agents in over 20 countries to sell and market its applications and to build, maintain and market their online business. For more information see www.sync2networks.com.
Legal Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.
Sync2 Networks, Develops Virtual Online Gaming Application, that will provide an integrated process for developing and distributing our applications through the AMPSC international agent network in over 20 countries. One of the company's key restructuring programs is being be implemented through the new Acquisition of the AMPSC Group lead by Sync2 networks, new president Mr. Ron Houle.
The JV partners in India will complement our North American team to provide a global application for our JV partners at VRX Simulators (www.vrx.ca) with such clients as Microsoft, Intel, AMD, Samsung, Indy and Nascar racing, just to name a few. This new virtual online gaming application will complement the Virtual Racer X Simulator platform.
This direction represents a corporate focus on the global gaming market and compliments the VRX Simulator partnership and development for a truly global application.
Mr. Houle has been working with VRX under a JV partnership with our Indian partners to develop an application to complement the VRX platform, where by the fiscal Racer X Racing simulator platform is used. Sync2 Networks with our India team will create a virtual online application where gaming and advertising come together and is fed directly into the online game as people around the world are playing in real time.
According to a recent report by market research firm iResearch currently, sales and subscriptions to Web-based games generate $353 million. Online-game advertisements generate between $450 million and $550 million, the research company said.
One segment that's giving the online-game industry a boost is "massively multiplayer online games". According to the Yankee study, in the United States alone, there will be 10 million people subscribing to these games by 2010, generating over $1.2 billion in revenue.
Last year, China's online gaming industry turned over 27.5 billion yuan (about 4.03 billion U.S. dollars) in 2009, according to Ma Huateng, president and CEO of China's leading Internet service provider Tencent Holdings Limited.
The global in-game advertising market, which generated $77.7 million globally in 2006, continues to develop at an exponential rate and will, by 2011, grow to $971.3 million in worldwide in-game advertising expenditures (fixed product placement/static ads and dynamic ads), according to a recent Yankee Group report.
About Sync2 Networks Corp.
Sync2 Networks is an online business development firm, which develops online Gaming and advertising applications. Sync2 through the AMPSC Group, also has a worldwide network of international marketing and business development agents in over 20 countries to sell and market its applications and to build, maintain and market their online business. For more information see www.sync2networks.com.
Legal Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.
SK3 Group Announces Healthcare of Today's Acquisition of MacuCLEAR
MIAMI, FLORIDA--(Marketwire - 01/07/10) - SK3 Group, Inc. (PINK SHEETS:SKTO - News) today announces that its new parent company, Healthcare of Today, Inc., has acquired MacuCLEAR, Inc., a pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye. SK3 has entered into a merger agreement with Healthcare of Today, Inc. under which both companies will merger into a new Nevada corporation, Healthcare of Today, Inc., formed for that purpose.
MC-1101, MacuCLEAR's primary product compound, is a patented, topically delivered drug for treating and stopping the progression of dry Age-related Macular Degeneration (AMD). MacuCLEAR (www.macuclear.com) has an active IND for MC-1101 and has completed a successful Phase Ib human clinical trial. The company's groundbreaking work leverages its unique understanding of ocular pharmacology and drug development to advance a pipeline of proprietary pharmaceuticals. MacuCLEAR's accomplished management team includes CTO George C. Y. Chiou, Ph. D., professor and director of the Institute of Ocular Pharmacology and professor of neuroscience and experimental therapeutics at Texas A&M University System Health Science Center. Dr. Chiou previously led the discovery of Timolol, a pioneering treatment for glaucoma.
The company's work on AMD comes at a crucial time in senior eye care. As the population ages and baby boomers advance into their 50s and 60s, the numbers suggest there will be a virtual epidemic of AMD. Age-related Macular Degeneration (AMD) is the most common cause of vision loss in people 50 and older. There are two forms of AMD: wet and dry. Currently, more than 15 million patients in the U.S. suffer from the signs and symptoms of AMD, while an estimated 25 to 30 million patients are afflicted worldwide. However, there is no approved drug treatment yet available to patients with dry AMD, and only limited treatments are available for patients with wet AMD. An astounding 90 percent of AMD patients cannot be treated with the methods currently available.
CEO of Healthcare of Today Henry Jan says, "MacuCLEAR is devoted to finding treatments for the millions of people who suffer from vascular disorders of the eye. This is a huge, under-served market, and they have the solutions. We are very proud to bring MacuCLEAR's groundbreaking work to the Healthcare of Today family, and we look forward to adding this new dimension to how we improve seniors' lives every day."
Healthcare of Today (http://www.healthcareoftoday.com), based in Burbank, California, is a vertically-integrated healthcare holding company. Founded in 2008, it has since acquired a number of companies, many specializing in the senior care industry. Its subsidiaries are engaged in a wide range of businesses including: nurse staffing, residential care facilities for the elderly, home healthcare services, home healthcare equipment sales, healthcare information technology, medical equipment, healthcare consulting, insurance, data security, advanced human tissue engineering, and more.
About SK3 Group, Inc.
SK3 Group also markets preferred medical services through its facilitation partners to its PEO client base. Corporate information can be found at http://www.sk3groupinc.com.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes", "expects", "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
MC-1101, MacuCLEAR's primary product compound, is a patented, topically delivered drug for treating and stopping the progression of dry Age-related Macular Degeneration (AMD). MacuCLEAR (www.macuclear.com) has an active IND for MC-1101 and has completed a successful Phase Ib human clinical trial. The company's groundbreaking work leverages its unique understanding of ocular pharmacology and drug development to advance a pipeline of proprietary pharmaceuticals. MacuCLEAR's accomplished management team includes CTO George C. Y. Chiou, Ph. D., professor and director of the Institute of Ocular Pharmacology and professor of neuroscience and experimental therapeutics at Texas A&M University System Health Science Center. Dr. Chiou previously led the discovery of Timolol, a pioneering treatment for glaucoma.
The company's work on AMD comes at a crucial time in senior eye care. As the population ages and baby boomers advance into their 50s and 60s, the numbers suggest there will be a virtual epidemic of AMD. Age-related Macular Degeneration (AMD) is the most common cause of vision loss in people 50 and older. There are two forms of AMD: wet and dry. Currently, more than 15 million patients in the U.S. suffer from the signs and symptoms of AMD, while an estimated 25 to 30 million patients are afflicted worldwide. However, there is no approved drug treatment yet available to patients with dry AMD, and only limited treatments are available for patients with wet AMD. An astounding 90 percent of AMD patients cannot be treated with the methods currently available.
CEO of Healthcare of Today Henry Jan says, "MacuCLEAR is devoted to finding treatments for the millions of people who suffer from vascular disorders of the eye. This is a huge, under-served market, and they have the solutions. We are very proud to bring MacuCLEAR's groundbreaking work to the Healthcare of Today family, and we look forward to adding this new dimension to how we improve seniors' lives every day."
Healthcare of Today (http://www.healthcareoftoday.com), based in Burbank, California, is a vertically-integrated healthcare holding company. Founded in 2008, it has since acquired a number of companies, many specializing in the senior care industry. Its subsidiaries are engaged in a wide range of businesses including: nurse staffing, residential care facilities for the elderly, home healthcare services, home healthcare equipment sales, healthcare information technology, medical equipment, healthcare consulting, insurance, data security, advanced human tissue engineering, and more.
About SK3 Group, Inc.
SK3 Group also markets preferred medical services through its facilitation partners to its PEO client base. Corporate information can be found at http://www.sk3groupinc.com.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes", "expects", "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Trustcash Announces Gross Revenues (Unaudited) for the Quarter Ending Dec 31, 2009
ATLANTA, GA--(Marketwire - 01/07/10) - TRUSTCASH HOLDINGS, INC. ("TRUSTCASH") (Pinksheets:TCHH - News) today confirms gross revenue (unaudited) for three month period ending December 31, 2009 was five hundred and thirty six thousand dollars ($536,000).
Trustcash Management stated, "We are pleased with our progress and accomplishments to date. We continue to develop a technology infrastructure focused on providing merchants with flexible online payment solutions. Our growth to date can be attributed to, amongst other things, Claudio Lai, our CTO. Claudio continues to manage our integration staff, development team and proprietary integration tools, ensuring timely deployment and support so our clients can focus on what they do best."
About Trustcash
The Trustcash(TM) platform delivers a sophisticated, comprehensive online payment processing system. The Trustcash technology infrastructure provides merchants with open access, PCI compliant payment processing. Trustcash(TM) is an E-Commerce expert providing online businesses with payment solutions needed to be successful.
Cautionary Statement Regarding Forward-Looking Statements
A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological changes and uncertainties related to the development of Trustcash's business model. The actual results Trustcash may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.
Trustcash Management stated, "We are pleased with our progress and accomplishments to date. We continue to develop a technology infrastructure focused on providing merchants with flexible online payment solutions. Our growth to date can be attributed to, amongst other things, Claudio Lai, our CTO. Claudio continues to manage our integration staff, development team and proprietary integration tools, ensuring timely deployment and support so our clients can focus on what they do best."
About Trustcash
The Trustcash(TM) platform delivers a sophisticated, comprehensive online payment processing system. The Trustcash technology infrastructure provides merchants with open access, PCI compliant payment processing. Trustcash(TM) is an E-Commerce expert providing online businesses with payment solutions needed to be successful.
Cautionary Statement Regarding Forward-Looking Statements
A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological changes and uncertainties related to the development of Trustcash's business model. The actual results Trustcash may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.
Wednesday, January 6, 2010
Photo Release -- Ingen Launches the New Oxyview Pulse Oximeter
Another Giant Leap for Ingen
YUCAIPA, Calif., Jan. 6, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today the introduction of the new Oxyview Pulse Oximeter.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6961
The Oxyview Pulse Oximeter is a very important and common device to check patient blood-oxygen saturation (SpO2) level and pulse rate. As a small, compact, simple, reliable and durable physiological monitoring device, the Oxyview Pulse Oximeter greatly enhances patient care, and fits both Adult and Pediatric patients. This small & lightweight design has a measurement range of 70% - 100%, and requires two AAA batteries. It has a Resolution of 1% with a measurement accuracy of 70% - 100%: +/- 3%. Some of the features include a dual color OLED display, display SpO2, PR, Pulse bar and Plethysmogram, 6 display modes, low power consumption, automatic power off, battery-low indicator, and an adjustable brightness feature.
This dynamic new product is the most sophisticated and cost competitive pulse oximeter in the market today. The company is selling the new device for $88.00, and when patients purchase the Oxyview Nasal Cannula they will earn points and receive the new Oxyview Pulse Oximeter at a discount. The market for this device includes the home oxygen patient market and the hospital markets.
"This new device will greatly enhance our revenues with expected sales of $1M in 2010, and increased sales with GSA contracts and our new distribution. The new Oxyview Pulse Oximeter has features that no other oximeter can offer, and the price is far less than that of any other Oximeter in its class," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
www.oxyviewnasalcannula.com
www.ingen-tech.com
About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
YUCAIPA, Calif., Jan. 6, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today the introduction of the new Oxyview Pulse Oximeter.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6961
The Oxyview Pulse Oximeter is a very important and common device to check patient blood-oxygen saturation (SpO2) level and pulse rate. As a small, compact, simple, reliable and durable physiological monitoring device, the Oxyview Pulse Oximeter greatly enhances patient care, and fits both Adult and Pediatric patients. This small & lightweight design has a measurement range of 70% - 100%, and requires two AAA batteries. It has a Resolution of 1% with a measurement accuracy of 70% - 100%: +/- 3%. Some of the features include a dual color OLED display, display SpO2, PR, Pulse bar and Plethysmogram, 6 display modes, low power consumption, automatic power off, battery-low indicator, and an adjustable brightness feature.
This dynamic new product is the most sophisticated and cost competitive pulse oximeter in the market today. The company is selling the new device for $88.00, and when patients purchase the Oxyview Nasal Cannula they will earn points and receive the new Oxyview Pulse Oximeter at a discount. The market for this device includes the home oxygen patient market and the hospital markets.
"This new device will greatly enhance our revenues with expected sales of $1M in 2010, and increased sales with GSA contracts and our new distribution. The new Oxyview Pulse Oximeter has features that no other oximeter can offer, and the price is far less than that of any other Oximeter in its class," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
www.oxyviewnasalcannula.com
www.ingen-tech.com
About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Subscribe to:
Posts (Atom)